Cardiff Oncology Financials
| XE7C Stock | EUR 4.65 0.16 0.00% |
Cardiff |
Understanding current and past Cardiff Oncology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cardiff Oncology's financial statements are interrelated, with each one affecting the others. For example, an increase in Cardiff Oncology's assets may result in an increase in income on the income statement.
The data published in Cardiff Oncology's official financial statements usually reflect Cardiff Oncology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cardiff Oncology. For example, before you start analyzing numbers published by Cardiff accountants, it's critical to develop an understanding of what Cardiff Oncology's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Cardiff Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cardiff Oncology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cardiff Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardiff Oncology. Please utilize our Beneish M Score to check the likelihood of Cardiff Oncology's management manipulating its earnings.
Cardiff Oncology Stock Summary
Cardiff Oncology competes with BioNTech, ASPEN TECHINC, KANDI TECHNOLOG, PARKEN Sport, and ADRIATIC METALS. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. CARDIFF ONCOLOG operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US14147L1089 |
| Business Address | 11055 Flintkote Avenue, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | NYSE Composite |
| Website | www.cardiffoncology.com |
| Phone | 858 952 7570 |
| Currency | EUR - Euro |
You should never invest in Cardiff Oncology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cardiff Stock, because this is throwing your money away. Analyzing the key information contained in Cardiff Oncology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cardiff Oncology Key Financial Ratios
Generally speaking, Cardiff Oncology's financial ratios allow both analysts and investors to convert raw data from Cardiff Oncology's financial statements into concise, actionable information that can be used to evaluate the performance of Cardiff Oncology over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cardiff Oncology reports annually and quarterly.| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Target Price | 25.33 |
Cardiff Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cardiff Oncology's current stock value. Our valuation model uses many indicators to compare Cardiff Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cardiff Oncology competition to find correlations between indicators driving Cardiff Oncology's intrinsic value. More Info.Cardiff Oncology is rated first in return on equity category among related companies. It is rated first in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cardiff Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cardiff Oncology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cardiff Oncology's earnings, one of the primary drivers of an investment's value.Cardiff Oncology Systematic Risk
Cardiff Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cardiff Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Cardiff Oncology correlated with the market. If Beta is less than 0 Cardiff Oncology generally moves in the opposite direction as compared to the market. If Cardiff Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cardiff Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cardiff Oncology is generally in the same direction as the market. If Beta > 1 Cardiff Oncology moves generally in the same direction as, but more than the movement of the benchmark.
About Cardiff Oncology Financials
What exactly are Cardiff Oncology Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cardiff Oncology's income statement, its balance sheet, and the statement of cash flows. Potential Cardiff Oncology investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cardiff Oncology investors may use each financial statement separately, they are all related. The changes in Cardiff Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cardiff Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Cardiff Oncology Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Cardiff Oncology is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Cardiff has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Cardiff Oncology's financials are consistent with your investment objective using the following steps:- Review Cardiff Oncology's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Cardiff Oncology's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Cardiff Oncology's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Cardiff Oncology's stock is overvalued or undervalued.
Cardiff Oncology April 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cardiff Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cardiff Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cardiff Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Cardiff Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cardiff Oncology's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.28 | |||
| Information Ratio | 0.2687 | |||
| Maximum Drawdown | 47.84 | |||
| Value At Risk | (7.92) | |||
| Potential Upside | 23.17 |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.Note that the Cardiff Oncology information on this page should be used as a complementary analysis to other Cardiff Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |